Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_assertion type Assertion NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_head.
- NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_assertion wasGeneratedBy ECO_0000203 NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_provenance.
- NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_assertion wasDerivedFrom befree-2016 NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_provenance.
- NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_assertion SIO_000772 12022239 NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_provenance.
- NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_assertion evidence source_evidence_literature NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_provenance.
- NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_assertion description "[Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP355556.RABzNueO-EwFYePjcj_Bo78cPF4WXGcFzkJ_7IjlCQKig130_provenance.